News
JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
2024.09.14
JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing
2024.09.10
JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity
2024.08.21
JHM Biopharmaceutical Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
2024.06.27
News
JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
2024.09.14
JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing
2024.09.10
JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity
2024.08.21
JHM Biopharmaceutical Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
2024.06.27